This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

Current Events

/Current Events

Mucopolysaccharidosis Type I (MPS I) Pilot Grant Program. One-year grants up to $150,000 (direct costs) will be available to develop novel nucleic and cell based treatments for MPS I.

The Orphan Disease Center (ODC) at the University of Pennsylvania is pleased to announce the Mucopolysaccharidosis Type I (MPS I) Pilot Grant Program. One-year grants up to $150,000 (direct costs) will be available to develop novel nucleic and cell based treatments for MPS I. The proposed therapeutic strategies should address the CNS manifestations of MPS I in patients with the severe [...]

Canadian Consensus Position Statement for the Diagnosis and Management of MPS II

June 15, 2018 VANCOUVER, BC – Today, the Canadian MPS Society issued a national consensus statement that provides updated Canadian guidelines for the management of patients with MPS II. A consensus meeting was held in Toronto, Ontario, including a multidisciplinary group of experts in the management of patients with MPS II. The group reviewed available published guidelines [...]

Regenxbio receives FDA fast track designation for RGX-111 gene therapy for the treatment of MPS I

June 12, 2018 at 5:36 PM EDT - Novel, one-time, direct-to-CNS investigational treatment for MPS I designed to prevent the progression of cognitive deficits- Phase I clinical trial expected to enroll children and adults with MPS I- Expect to initiate patient recruitment and dosing in mid-2018 ROCKVILLE, Md., June 12, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), [...]

Rare – 15th Annual Ignite Hope Fundraising Gala

RARE - 15th Annual Ignite Hope Fundraising Gala What does RARE mean to you..... special? unusual? out of the ordinary? unique? uncommon? ......but it has special meaning for those affected by MPS and related disorders. Please join us in celebrating RARE on Saturday, May 26th, 2018 Please click here to purchase tickets. Look forward to [...]

ArmaGen Update on Hurler Syndrome Development Program

AGT-181: Investigational Therapy for the Treatment of Patients with Hurler Syndrome AGT-181 is an investigational enzyme replacement therapy designed to treat both the body-related and central nervous system-related symptoms and complications of MPS I. Currently approved treatments for MPS I are unable to penetrate the blood-brain barrier (BBB), a filter that protects the brain from harmful substances like toxins and bacteria but allows [...]

Live Your Best Life National Family Conference

Live Your Best Life Join us July 21-23, 2017 Founded in 1984, The Canadian Society for Mucopolysaccharide and Related Diseases Inc. (The Canadian MPS Society) is committed to providing support to individuals and families affected with Mucopolysaccharide (MPS) and related diseases. Our bi-annual conferences give families affected by MPS & related diseases an opportunity to [...]